These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 20878304

  • 1. [Very severe thrombotic thrombocytopenic purpura (TTP) after H1N1 vaccination].
    Hermann R, Pfeil A, Busch M, Kettner C, Kretzschmar D, Hansch A, La Rosée P, Wolf G.
    Med Klin (Munich); 2010 Sep; 105(9):663-8. PubMed ID: 20878304
    [Abstract] [Full Text] [Related]

  • 2. [Rituximab as effective therapy in very severe thrombotic thrombocytopenic purpura (TTP)].
    Illner N, Wolf G.
    Dtsch Med Wochenschr; 2010 May; 135(3):71-4. PubMed ID: 20077379
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Rituximab provided long-term remission in a patient with severe thrombotic thrombocytopenic purpura refractory to plasma exchange].
    Hong H, Aoyama Y, Yamamura R, Ohta T, Mugitani A, Yamane T, Hino M, Matsumoto M, Fujimura Y.
    Rinsho Ketsueki; 2006 Dec; 47(12):1528-32. PubMed ID: 17233471
    [Abstract] [Full Text] [Related]

  • 5. Acquired Thrombotic Thrombocytopenic Purpura Without Anti-ADAMTS13 Antibody Caused by Influenza A (H1N1) Virus Successfully Treated by Plasma Exchange: A Case Report.
    Kubo K, Abe T, Kawano N, Ochiai H.
    Am J Case Rep; 2021 Aug 02; 22():e932251. PubMed ID: 34334786
    [Abstract] [Full Text] [Related]

  • 6. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies.
    Bresin E, Gastoldi S, Daina E, Belotti D, Pogliani E, Perseghin P, Scalzulli PR, Paolini R, Marcenò R, Remuzzi G, Galbusera M.
    Thromb Haemost; 2009 Feb 02; 101(2):233-8. PubMed ID: 19190804
    [Abstract] [Full Text] [Related]

  • 7. Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura.
    Kosugi S, Matsumoto M, Ohtani Y, Take H, Ishizashi H, Fujimura Y, Kuyama J.
    Int J Hematol; 2005 Jun 02; 81(5):433-6. PubMed ID: 16158827
    [Abstract] [Full Text] [Related]

  • 8. Goodpasture's syndrome associated with thrombotic thrombocytopenic purpura secondary to an ADAMTS-13 deficit.
    Vega-Cabrera C, Del Peso G, Bajo A, Picazo ML, Rivas-Becerra B, Benitez AL, Ara JM, Olea T, Selgas R.
    Int Urol Nephrol; 2013 Dec 02; 45(6):1785-9. PubMed ID: 23111709
    [Abstract] [Full Text] [Related]

  • 9. ADAMTS13 deficiency and thrombotic thrombocytopenic purpura associated with trimethoprim-sulfamethoxazole.
    Bapani S, Epperla N, Kasirye Y, Mercier R, Garcia-Montilla R.
    Clin Med Res; 2013 Jun 02; 11(2):86-90. PubMed ID: 23262188
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Current insight into thrombotic thrombocytopenic purpura.
    Verbeke L, Delforge M, Dierickx D.
    Blood Coagul Fibrinolysis; 2010 Jan 02; 21(1):3-10. PubMed ID: 19851089
    [Abstract] [Full Text] [Related]

  • 14. Thrombotic thrombocytopenic purpura and other thrombotic microangiopathic hemolytic anemias: diagnosis and classification.
    Shenkman B, Einav Y.
    Autoimmun Rev; 2014 Jan 02; 13(4-5):584-6. PubMed ID: 24418304
    [Abstract] [Full Text] [Related]

  • 15. [Thrombotic-thrombocytopenic purpura].
    Hellmann M, Hallek M, Scharrer I.
    Internist (Berl); 2010 Sep 02; 51(9):1136, 1138-44. PubMed ID: 20689903
    [Abstract] [Full Text] [Related]

  • 16. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.
    Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, Mackie I, Machin SJ.
    Br J Haematol; 2007 Feb 02; 136(3):451-61. PubMed ID: 17233847
    [Abstract] [Full Text] [Related]

  • 17. Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura.
    Becerra E, Scully MA, Leandro MJ, Heelas EO, Westwood JP, De La Torre I, Cambridge G.
    Clin Exp Immunol; 2015 Mar 02; 179(3):414-25. PubMed ID: 25339550
    [Abstract] [Full Text] [Related]

  • 18. First diagnosis of thrombotic thrombocytopenic purpura after SARS-CoV-2 vaccine - case report.
    Osmanodja B, Schreiber A, Schrezenmeier E, Seelow E.
    BMC Nephrol; 2021 Dec 11; 22(1):411. PubMed ID: 34895163
    [Abstract] [Full Text] [Related]

  • 19. Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura.
    Coppo P, Veyradier A.
    Presse Med; 2012 Mar 11; 41(3 Pt 2):e163-76. PubMed ID: 22265954
    [Abstract] [Full Text] [Related]

  • 20. [Refractory thrombotic thrombocytopenic purpura successfully treated with a combination of rituximab and vincristine].
    Kaneko H, Matsumoto M, Okamoto K, Chyonabayashi K, Hishizawa M, Watanabe M, Fujimura Y, Tsudo M.
    Rinsho Ketsueki; 2007 Feb 11; 48(2):144-7. PubMed ID: 17370643
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.